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Specification of the T helper 17 (Th17) cell lineage
requires a well-defined set of transcription factors,
but how these integrate with posttranscriptional and
epigenetic programs to regulate gene expression
is poorly understood. Here we found defective Th17
cell cytokine expression in miR-155-deficient CD4+
T cells in vitro and in vivo. Mir155 was bound by
Th17 cell transcription factors and was highly ex-
pressed during Th17 cell differentiation. miR-155-
deficient Th17 andT regulatory (Treg) cells expressed
increased amounts of Jarid2, a DNA-binding protein
that recruits the Polycomb Repressive Complex 2
(PRC2) to chromatin. PRC2 binding to chromatin
and H3K27 histone methylation was increased in
miR-155-deficient cells, coinciding with failure to ex-
press Il22, Il10, Il9, andAtf3. Defects in Th17 cell cyto-
kine expression and Treg cell homeostasis in the
absence of Mir155 could be partially suppressed by
Jarid2 deletion. Thus, miR-155 contributes to Th17
cell function by suppressing the inhibitory effects of
Jarid2.
INTRODUCTION
The mammalian adaptive immune response is critical for host
defense against pathogens, with CD4+ T cells playing important
roles in an array of helper, effector, and regulatory functions. In
response to specific stimuli, CD4+ T cells have the potential to
differentiate into several different cell fates that include the T
helper 1 (Th1), Th2, Th17, and T regulatory (Treg) cell lineages.
Defective differentiation of CD4+ T cells results in human immu-
nodeficiency such as in autosomal-dominant hyper-IgE or Job
syndrome, where Th17 cell specification is impaired due to
STAT3 loss of function (Milner et al., 2008) and mutations in
FOXP3 result in immunodysregulation, polyendocrinopathy, en-teropathy, X-linked (IPEX) syndrome, due to a defect in Treg cells
(Bennett et al., 2001; Brunkow et al., 2001; Wildin et al., 2001).
Therefore, understanding the molecular basis of CD4+ Th cell
differentiation will provide key information about subset specifi-
cation and facilitate the design of more effective strategies for
targeting autoimmunity and augmenting immunizations.
The specification of distinct CD4+ Th cell lineages is orches-
trated by a regulatory network that integrates signals from the
extracellular cytokine milieu, T cell receptor engagement, and
costimulatory ligands to achieve a series of programmed gene
expression changes (Zhu et al., 2010). Transcriptional and epige-
netic programs initiated within CD4+ T cells promote changes in
gene expression, ultimately resulting in production of their signa-
ture cytokines (Ciofani et al., 2012; Kanno et al., 2012; Yosef
et al., 2013). In this process, microRNAs (miRNAs) provide a
layer of posttranscriptional gene expression control that needs
to be considered (Cobb et al., 2006; Muljo et al., 2005).
Recently, a core transcription factor network necessary for
Th17 cell differentiation was elucidated (Ciofani et al., 2012).
However, the roles of miRNAs and chromatin regulators have
not been integrated with this transcriptional network. In Th17
cell responses, miR-155 has been shown to promote the
production of interleukin-17 (IL-17) and interferon-g (IFN-g) in
Helicobacter pylori infection (Oertli et al., 2011) as well as mouse
models of inflammatory diseases (Blu¨ml et al., 2011; Escobar
et al., 2013; Murugaiyan et al., 2011; O’Connell et al., 2010).
However, the mechanisms by which miR-155 acts in Th17 cells
are not clear.
Here, we performed unbiased transcriptomic analyses
comparing wild-type (WT) and miR-155-deficient Th17 cells
and found Jumonji, AT Rich Interactive Domain 2 (Jarid2) to be
upregulated in the absence of miR-155. Jarid2 was recently
discovered to be essential for recruiting PRC2 to genomic sites
in embryonic stem (ES) cells (Landeira et al., 2010; Li et al.,
2010; Pasini et al., 2010; Peng et al., 2009; Shen et al., 2009).
However, the function of Jarid2 in adult somatic cells such as
lymphocytes is not known. Analysis of Jarid2-deficient CD4+
T cells combined with chromatin immunoprecipitation (ChIP)
analyses allowed us to identify direct targets of PRC2 in Th17
cells. Furthermore, deletion of Jarid2 in the miR-155-deficientImmunity 40, 865–879, June 19, 2014 ª2014 Elsevier Inc. 865
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Epigenetic Reprogramming by Jarid2CD4+ T cells results in partial rescue of Th17 cell-associated
cytokine expression as well as homeostasis of Treg cells.
Thus, we demonstrate that miR-155 and Jarid2 form a regulatory
circuit that can control lineage-specific gene expression in CD4+
T cells through its effect on Polycomb recruitment.
RESULTS
miR-155-Deficient CD4+ T Cells Have Cell-Intrinsic
Defects
To determine whether miR-155 plays a cell-autonomous role in
CD4+ T cells in vivo, we generated mixed bone marrow (BM)
chimeras and examined miR-155-deficient and WT CD4+
T cells within the same host (Figures S1A and S1B available
online). As previously reported (Kohlhaas et al., 2009; Lu et al.,
2009), we found that miR-155-deficient Treg cells have a
competitive disadvantage compared with their WT counterparts
(Figures S1C). In contrast, we did not observe differential fitness
of congenic WT CD45.1+ and WT CD45.2+ cells in control mixed
BM chimeras (data not shown).
In these mixed BM chimeras, we studied a population
of Th17 cells present in the mesenteric lymph nodes (MLNs).
Flow cytometry of restimulated CD4+TCRb+CD44+ T cells
from the MLN revealed a deficit in RORgt+IL-17A+ cytokine-
producing Th17 cells among the miR-155-deficient population
compared to WT (Figures 1A and 1B). No significant change
in RORgt+IL-17A– Th cells that have undergone lineage specifi-
cation was observed. We also found a cell-autonomous defect
in the production of both IL-17A and IL-22 by miR-155-defi-
cient CD4+ T cells upon restimulation ex vivo (Figures 1C and
1D). Therefore, CD4+ cells deficient in miR-155 display cell-
intrinsic defects in Treg cell homeostasis and Th17 cytokine
expression.
miR-155-Deficient CD4+ T Cells Are Th1 Cell Competent
upon Infection with Toxoplasma gondii
Previously, miR-155-deficient CD4+ T cells were reported to
have a defect in IFN-g and IL-17A expression after H. pylori
infection (Oertli et al., 2011). Furthermore, miR-155 is impli-
cated in the development of collagen-induced arthritis and
of experimental autoimmune encephalomyelitis and uveitis
(Blu¨ml et al., 2011; Escobar et al., 2013; Murugaiyan et al.,
2011; O’Connell et al., 2010). Because Th1 and Th17 cells can
contribute to pathogenesis in these mouse models, it is
currently unclear whether miR-155 contributes to development
of one or both of these T cell subsets. To address this issue,
we employed the murine model of peroral Toxoplasma gondii
infection, which is known to induce a highly polarized Th1
effector cell population as well as a localized Th17 cell response
in the small intestine (Liesenfeld, 2002). Analysis of CD4+TCRb+
CD44+ T cells from the MLN at 8 days after oral infection
revealed comparable IFN-g production by both WT and miR-
155-deficient cells (Figures S1D and S1E). Furthermore, there
were similar frequencies of T. gondii-specific IFN-g-producing
CD4+ cells among WT and Mir155-deficient populations
(Figure S1E). Thus, we found that miR-155 deletion does not
significantly impair the Toxoplasma-specific Th1 cell response.
Similar to uninfected chimeras, Foxp3+ Treg cells were reduced
among the miR-155-deficient population (Figure S1F). Analysis866 Immunity 40, 865–879, June 19, 2014 ª2014 Elsevier Inc.of CD4+TCRb+CD44+ T cells in the lamina propria of the small
intestine (siLP) revealed a cell-intrinsic defect in IL-17A and IL-
22 production among the miR-155-deficient population upon
restimulation (Figures 1E and 1F). These data demonstrate
that miR-155 is specifically required for Treg cell homeostasis
and induction of Th17 cell cytokine expression but is dispens-
able for the antigen-specific Th1 cell response upon peroral
infection of T. gondii.
miR-155 Is Highly Expressed in Mouse and Human Th17
Cells
Because of the defect in Th17 cells, we hypothesized that miR-
155 may be differentially expressed among CD4+ T cell subsets.
We found high expression of miR-155 in both the mouse and
human Th17 cell cultures relative to Th1, Th2, Th17, or trans-
forming growth factor b (TGF-b)-induced Treg (iTreg) cells (Fig-
ures 1G and 1H). The expression of miR-155 increased over
time during polarization of both primary mouse and human
Th17 cell cultures (Figures 1I and 1J). To determine the molec-
ular basis for the high expression in Th17 cells, we examined the
genomic localization of Th17-cell-associated transcription fac-
tors, which include signal transducer and activator of tran-
scription 3 (STAT3), interferon regulatory factor 4 (IRF4), basic
leucine zipper transcription factor, ATF-like (BATF), v-maf mus-
culoaponeurotic fibrosarcoma oncogene homolog (c-MAF), and
retinoic acid receptor-related orphan receptor gamma t isoform
(RORgt) in published ChIP-seq data (Ciofani et al., 2012). We
found evidence that the Mir155 locus is directly bound by
STAT3, c-MAF, BATF, and IRF4, transcription factors essential
during the early phase of Th17 cell differentiation (Figure S2A).
The transcription factor binding profile at the Mir155 locus
is similar to the Rorc gene that encodes a Th17-cell-specific
master regulator (Figure S2B).
IL-17, but Not IL-22, Expression in miR-155-Deficient
Th17 Cells Can Be Rescued by IL-1 Signaling
To investigate the mechanism of action for miR-155, we polar-
ized CD4+ T cells from miR-155-deficient mice and littermate
controls toward the Th17 cell fate as previously described with
IL-6 and TGF-b cytokines (Korn et al., 2007; Nurieva et al.,
2007; Veldhoen et al., 2006). Because IL-1b promotes the in vivo
development of Th17 cells (Ben-Sasson et al., 2009; Chung
et al., 2009; Shaw et al., 2012), we also tested the effects of
adding or withholding exogenous IL-1b to Th17 cell cultures.
Differentiating miR-155-deficient Th17 cell cultures without
exogenous IL-1b resulted in reduced IL-17A production (Fig-
ure 2A), as reported previously (O’Connell et al., 2010). We found
that miR-155-deficient Th17 cell cultures without IL-1b could
generate RORgt+ T cells, but they have a defect in producing
IL-17A upon restimulation, similar to our results in the in vivo
mixed BM chimera study (Figure 2A). This defect can be rescued
upon addition of exogenous IL-1b to the differentiation condi-
tions (Figure 2B). IL-1b did not affect cell survival or proliferation
(Figures S2C and S2D) and there was no significant variation
in absolute cell numbers in the cultures (data not shown).
In addition, we found that transcripts encoding RORgt, BATF,
and IRF4 remained stable in the absence of miR-155 in either
condition (Figures S2E and S2F). However, without exogenous
IL-1b, Il17a, Il17f, Il1r1, and Il22 transcripts were decreased in
Figure 1. miR-155 Is Expressed by Th17 Cells and Required for Th17-Cell-Associated Cytokine Expression
(A and B) FACS analysis (A) and percentages and absolute cell numbers (B) ofMir155+/+ (CD45.1+) orMir155/ (CD45.2+) CD4+TCRb+CD44+ cells in the MLN of
mixed BM chimeras to enumerate IL-17A- and/or RORgt-expressing cells (n = 5).
(C and D) FACS analysis (C) and percentages and absolute cell numbers (D) of CD4+TCRb+CD44+ cells that express IL-17A and/or IL-22 among WT and
Mir155/ cells in the MLN of mixed BM chimeras (n = 5).
(E and F) FACS analysis (E) and percentages and absolute cell numbers (F) of CD4+TCRb+CD44+ cells that express IL-17A and/or IL-22 in the siLP of mixed BM
chimeras from Toxoplasma-infected mice.
(G–J) qRT-PCR analysis of mature miR-155 expression normalized to U6 small nuclear RNA from the indicated mouse (G) or human (H) CD4+ T cell subsets
polarized ex vivo, or during mouse (I) and human (J) Th17 cell differentiation over a time course of 4 and 5 days, respectively.
Error bars represent mean ± SEM. Statistical significance was determined by unpaired Student’s t test (*p < 0.05 and **p < 0.01).
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ure 2C). With the exception of Il22, each of these miR-155-
dependent gene expression defects were rescued by addingIL-1b to our cultures (Figure 2D). Collectively, these results sug-
gest that IL-1 signaling can partially bypass the need for miR-
155, perhaps via an alternate parallel pathway.Immunity 40, 865–879, June 19, 2014 ª2014 Elsevier Inc. 867
Figure 2. IL-1 Signaling Can Partially Rescue Gene Expression Defects in miR-155-Deficient Th17 Cells
(A and B) FACS analysis and percentages of CD4+CD44+ T cells expressing IL-17A and RORgt inMir155/ or WT Th17 cell cultures polarized without (A) or with
(B) exogenous IL-1b.
(C and D) qRT-PCR analyses of Il17a, Il17f, Il1r1, and Il22 in Mir155/ or WT Th17 cell cultures polarized without (C) or with (D) IL-1b.
Relative expression was calculated by normalizing to Gapdh. Error bars represent mean ± SEM. Statistical significance was determined by Student’s t test
(*p < 0.05, **p < 0.01, and ****p < 0.0001).
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Epigenetic Reprogramming by Jarid2Il22Transcription IsReduced inmiR-155-Deficient Th17
Cell Cultures
To systematically determine the consequences of Mir155 dele-
tion on gene expression, we conducted whole-transcriptome
RNA sequencing (RNA-seq) of miR-155-deficient and WT Th17
cell cultures with IL-1b. As a result, we found 553 and 551 tran-
scripts that are up- and downregulated, respectively, in miR-
155-deficient Th17 cell cultures compared to WT controls
(Figure 3A). In the absence of miR-155, most of the known
Th17-cell-associated transcription factors and the IL-17 cyto-
kines were unaffected (Figure 3A). However, RNA-seq revealed
reduced expression of Il22, Il10, and Il9 in miR-155-deficient
Th17 cell cultures (Figures 3A and 3B), and these findings were
validated by qRT-PCR (Figures S3A and S3B).
We first focused on Il22 gene expression because it was the
most differentially expressed transcript between miR-155-defi-868 Immunity 40, 865–879, June 19, 2014 ª2014 Elsevier Inc.cient and WT Th17 cell cultures. IL-22 production could be
regulated via several mechanisms. To measure recently tran-
scribed Il22, we performed qRT-PCR of unspliced transcripts
by using primers that amplified an intron of Il22, and we found
that it was decreased in miR-155-deficient Th17 cell cultures
compared to WT (Figure 3C). Next, we performed chromatin
immunoprecipitation (ChIP) of RNA polymerase (pol) II at the
Il22 transcriptional start site (TSS) and found decreased occu-
pancy in the absence of miR-155 (Figure 3D). Furthermore, as
another indication that the Il22 promoter is less active in miR-
155-deficient Th17 cells, we found less histone H3 lysine 4 trime-
thylation (H3K4me3) (Figure 3E). Taken together, our data are
consistent with a reduction in Il22 transcription in miR-155-defi-
cient Th17 cell cultures.
Given the above results, we hypothesized that miR-155 tar-
gets a transcriptional repressor of Il22. We considered c-MAF
Figure 3. RNA-seq of miR-155-Deficient and WT Th17 Cells Identifies Altered Cytokine Expression and Putative miR-155 Targets
(A) Scatter plot of gene expression for 20,096 RefSeq transcripts inMir155/ andWT Th17 cell culturesmeasured by RNA-seq. Notable transcription factors and
cytokines are highlighted. Dashed red lines indicate a fold change of 2.
(B) Genome browser screenshots of Il22, Il10, and Il9 loci depict RNA-seq results as normalized coverage tracks in Mir155/ (red) and WT (blue) Th17 cell
cultures.
(C) qRT-PCR of Il22 intron 4 ± reverse transcriptase (RT) in Mir155/ and WT Th17 cultures (+ IL-1b).
(D and E) ChIP-qPCR of RNA polymerase II (Pol II) at Il22 TSS (D) or H3K4me3 at Il22 promoter (E) in Mir155/ and WT Th17 cell cultures.
(F) Immunoblot analysis for c-MAF, SOCS1, and SHIP1 inMir155/ andWT Th17 cell cultures with protein expression quantitated by ImageJ and normalized to
Tubulin as a control.
(G) Genome browser screenshots of c-MAF peaks in the Il22 and Il17a loci inMir155/ (red) and WT (blue) Th17 cell cultures. Arrows mark the regions validated
by ChIP-qPCR.
(H) Enrichment of Il22 and Il17a promoter was measured by ChIP-qPCR of c-MAF in Mir155/ or WT Th17 cell cultures.
(I) Relative expression of Il22 and Cyp1a1mRNA normalized to Gapdh was determined by qRT-PCR inMir155/ or WT Th17 cell cultures (+ IL-1b) and treated
with DMSO or 0.3 mM of FICZ.
Error bars represent mean ± SEM. Statistical significance was determined by Student’s t test (**p < 0.01, ***p < 0.001; ns denotes not significant).
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Epigenetic Reprogramming by Jarid2as a reasonable candidate, because it was previously reported
as a target of miR-155 as well as a repressor of Il22 transcription
(Rodriguez et al., 2007; Rutz et al., 2011). Indeed, we observed a
1.6-fold upregulation in c-MAF transcripts in miR-155-deficientTh17 cell cultures compared to WT by RNA-seq (Figure S3C),
and a 2.4-fold upregulation of c-MAF protein by immunoblot
analysis (Figure 3F). In contrast, Inositol Polyphosphate-5-Phos-
phatase 1 (SHIP1 encoded by Inpp5d) and Suppressor OfImmunity 40, 865–879, June 19, 2014 ª2014 Elsevier Inc. 869
Figure 4. Jarid2 Recruits PRC2 to Epigenetically Silence the Il22 Locus in the Absence of miR-155
(A) Sylamer analysis ofMir155/ and WT Th17 cell RNA-seq is depicted as a landscape plot: hypergeometric significance values for enrichment of heptamers
among 30 UTRs of genes (y axis) and genes sorted frommost upregulated inMir155/ to downregulated (x axis). Two heptamericmotifs are significantly enriched
in genes upregulated inMir155/ Th17 cell cultures (red and orange lines). The horizontal dotted red line represents an E-value threshold of p < 0.01 (Bonferroni-
corrected for multiple testing). Vertical dotted lines indicate log2 fold change cutoffs of differentially expressed transcripts.
(B) Comparison of our gene list from Sylamer analysis with predictions from TargetScan and Pictar, showing an overlap of 15 genes with putative miR-155
binding sites.
(C) Relative expression of Jarid2 mRNA was determined by qRT-PCR in Mir155/ or WT Th17 cell cultures (+ IL-1b).
(D) Immunoblot analysis of Jarid2 protein in Mir155/ and WT Th17 lysates quantified by ImageJ and Tubulin as a loading control.
(E) Relative expression of Jarid2 mRNA in Treg cells was determined by qRT-PCR in Mir155/ or WT CD4+CD25+ T cells sorted from the spleen.
(F) Genome browser screenshots depict Jarid2, Suz12, and H3K27me3 enrichment at the Il22 locus. Arrows indicate promoter, proximal, and distal regions
validated by qPCR.
(legend continued on next page)
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Epigenetic Reprogramming by Jarid2Cytokine Signaling 1 (SOCS1), other known miR-155 targets (Lu
et al., 2009; O’Connell et al., 2009), were not differentially ex-
pressed (Figure 3F). Thus, we considered c-MAF as a viable
miR-155 target in Th17 cells.
ChIP-seq was conducted to map c-MAF binding to the
genome. In total, about 12,554 and 8,815 c-MAF peaks were
identified in WT and miR-155-deficient Th17 cells, respectively
(FigureS3D).Surprisingly, therewere fewerpeaksof c-MAFbind-
ing although c-MAF was overexpressed in the absence of miR-
155. Importantly, we determined that c-MAF failed to bind to
the Il22 locus in miR-155-deficient Th17 cell cultures (Figure 3G).
As a control, we did not observe a difference in c-MAF binding to
the Il17a locus under these culture conditions (Figure 3G). ChIP
findings were validated by qPCR (Figure 3H). Thus, c-MAF is
not responsible for silencing Il22 in the absence of miR-155.
The aryl hydrocarbon receptor (AHR) plays a critical role in Il22
transcription (Veldhoen et al., 2008), and therefore we asked
whether stimulating the activity of this transcription factor could
rescue Il22 expression in miR-155-deficient Th17 cells. We
found that upon ligation of AHR by an agonist, 6-formylindolo
[3,2-b]carbazole (FICZ), the expression of Il22 is increased but
still impaired in miR-155-deficient Th17 cells compared to WT
(Figure 3I). In contrast, the canonical AHR target, Cyp1a1, was
not differentially regulated in miR-155-deficient and WT Th17
cell cultures with or without FICZ treatment (Figure 3I). These re-
sults suggest that AHR activity is specifically inhibited at the Il22
locus and may contribute to the inability of miR-155-deficient
Th17 cells to express Il22.
Motifs Matching the miR-155 Seed Sequence Are
Enriched in 30 UTR of Genes Upregulated in
miR-155-Deficient Th17 Cells
To look for additional potential targets of miR-155, we used the
computational tool Sylamer, which searches for correlations be-
tween gene expression changes in our RNA-seq data set and the
enrichment of sequence motifs in the 30 UTR of the correspond-
ing genes (van Dongen et al., 2008). As a testament to the spec-
ificity of this analysis, we found that out of the 970 heptameric
seed sequences tested, only the two overlapping motifs that
match the miR-155 seed sequence (50-AGCATTA-30 and 50-
GCATTAA-30) were significantly enriched in genes upregulated
in miR-155-deficient compared to WT Th17 cell cultures (Fig-
ure 4A). This Sylamer analysis revealed 220 transcripts upregu-
lated in miR-155-deficient Th17 cell cultures that contain at least
one miR-155 seed sequence in their 30 UTR. To further narrow
down the putative miR-155 targets, we compared our gene list
with two computational miRNA target prediction methods that
invoke evolutionary conservation: TargetScan and PicTar (Fig-
ure 4B; Krek et al., 2005; Lewis et al., 2003). Intersection of
the gene lists from Sylamer, TargetScan, and PicTar yielded
only 15 common putative targets (Figure S4A). In conclusion,
we could readily detect a signature of miR-155-mediated tuning
within the transcriptome of Th17 cell cultures and identified a
short list of candidates for further testing.(G–L) Enrichment of anti-Jarid2 (G and H), anti-Suz12 (I and J), and anti-H3K27me
at three indicated locations within Il22 locus or the Il17a promoter was determine
Error bars represent mean ± SEM. Validations were normalized to input controls a
significance determined by unpaired Student’s t test (*p < 0.05, **p < 0.01, ***p <The DNA-Binding Protein Jarid2 Is Enriched in
miR-155-Deficient Th17 Cell Cultures
Based on our hypothesis that miR-155 is targeting a transcrip-
tional repressor of Il22, we considered four candidate DNA-bind-
ing proteins: Bach1, Jarid2, Sp3, and Tle4 (Figure S4A). Jarid2
was investigated further because it is the most highly expressed
in Th17 cells of the four candidates (Figure S4B). In mouse ES
cells, Jarid2 recruits the histone-modifying holoenzyme PRC2
to specific sites in the genome and silences transcription of its
target genes through histone 3 lysine 27 (H3K27) trimethylation
mediated by the polycomb proteins enhancer of zeste homolog
1 (Ezh1) or Ezh2 (Landeira et al., 2010; Li et al., 2010; Pasini et al.,
2010; Peng et al., 2009; Shen et al., 2009). Jarid2 was previously
validated to be a miR-155 target in chicken and human cells
(Bolisetty et al., 2009). According to the TargetScan and Pictar
databases, two heptameric miR-155 seed sequences are
conserved in the 30 UTR of Jarid2 with the upstream predicted
site being better conserved (Figure S4C). Furthermore, it
was demonstrated by high-throughput sequencing of RNA
isolated by crosslinking and immunoprecipitation (HITS-CLIP)
that Argonaute2 (Ago2), a key protein of the miRNA-induced
silencing complex (miRISC), directly binds to the upstream pre-
dicted site in 30 UTR of Jarid2 in activated WT CD4+ T cells (Fig-
ure S4D; Loeb et al., 2012). The binding of Ago2 to this site is
dependent on miR-155 as shown by the fact that it is eliminated
in miR-155-deficient T cells (Figure S4D). Notably, we found that
Jarid2 transcripts and protein levels are both upregulated inmiR-
155-deficient Th17 cultures by about 2-fold (Figures 4C and 4D).
Jarid2 transcripts are also elevated in miR-155-deficient Treg
cells (Figure 4E).
ChIP-seq analyses was conducted to determine whether
Jarid2 directly targets Il22 in Th17 cell cultures. We found
increased association of Jarid2 with the Il22 locus in miR-155-
deficient cells (Figure 4F) and validated enrichment by qPCR at
three genomic locations (Figure 4G). Jarid2 did not preferentially
bind to the Il17a promoter in miR-155-deficient Th17 cell cul-
tures, consistent with normal expression of IL-17A in these cells
(Figure 4H). To determine whether Jarid2 silences Il22 transcrip-
tion by recruiting PRC2, we conducted ChIP-seq for Suppressor
of Zeste 12 (Suz12), a core component of PRC2 (Figure 4F).
Analyses at the same genomic locations as Jarid2 confirmed
increased association of Suz12with the Il22 locus in the absence
of miR-155 (Figure 4I), but not at the Il17a promoter (Figure 4J).
Higher amounts of H3K27 trimethyl (H3K27me3) were detected
at the Il22 locus in miR-155-deficient Th17 cell cultures (Figures
4F and 4K), whereas H3K27me3 at the Il17a promoter was
unaffected (Figure 4L).
Jarid2 and PRC2 Reprogram the Epigenome of
miR-155-Deficient Th17 Cells
Because the direct targets of PRC2 in CD4+ T cells have not been
systematically examined, we performed ChIP-seq analyses for
Jarid2, Suz12, and H3K27me3 in miR-155-deficient Th17 cell
cultures and their WT controls. Our analysis identified 6,7863 (K and L) along with control IgG ChIPs ofMir155/ andWT Th17 cell cultures
d by qPCR.
nd results are representative of three independent experiments with statistical
0.001, and ****p < 0.0001; ns denotes not significant).
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Epigenetic Reprogramming by Jarid2and 4,070 Jarid2 islands, 13,206 and 14,862 Suz12 islands,
and 4,495 and 4,335 H3K27me3 islands in WT and miR-155-
deficient Th17 cells, respectively (Figure 5A). Correlating with
the increased Jarid2 expression, we found augmented Jarid2
islands as well as Suz12 and H3K27me3 islands when
comparing the miR-155-deficient to WT Th17 cells (Figure 5A).
To identify genes directly targeted by PRC2, we looked for
Jarid2, Suz12, and H3K27me3 islands that increased in miR-
155-deficient Th17 cell cultures that were colocalized ±10 kb
from a gene body (Figure 5A). This list included canonical
PRC2 target genes, such as the HoxA-D gene clusters (Figures
5B and S5A–S5C) and embryonic genes including Gata6 and
Sox17 (Figures S5D and S5E). PRC2 also targeted Tal1, a tran-
scription factor gene essential for the specification of hemato-
poietic stem cells (HSCs) that is silenced upon differentiation
(Figure 5C). Jarid2-PRC2 bound to genes such as Eomes and
Tbx21 that may mediate Th17 cell fate plasticity (Figures S5F
and S5G). In summary, we found that Jarid2 upregulation in
miR-155-deficient Th17 cells resulted in widespread increased
recruitment of the Jarid2-PRC2 holoenzyme that coincided
with increased deposition of H3K27me3 at specific sites
throughout the genome.
In addition to Il22, Il10 and Il9were also directly targeted by the
Jarid2-PRC2 holoenzyme (Figures 5D and 5E). In addition, we
found genes not yet known to play a role in Th17 cells, such as
Atf3 encoding activating transcription factor 3 (ATF3), a member
of the AP-1 superfamily of leucine zipper proteins that includes
Fos, Jun, and BATF. Atf3 was targeted by PRC2 (Figure 5F)
and its expression was reduced in miR-155-deficient Th17 cells
as determined by RNA-seq (data not shown) and qRT-PCR (Fig-
ure 5G). Atf3 expression was induced in Th17 cells differentiated
in the presence of exogenous IL-1b (Figure S5H). To determine
the role of Atf3 in Th17 cells, we used a retroviral vector to over-
express Atf3 (ATF3-rv) during Th17 cell differentiation. Th17
cell cultures transduced with ATF3-rv expressed more IL-17A
compared to the empty virus control (Figure 5H) and untrans-
duced cells in the same cultures (data not shown). Conversely,
deletion of Atf3 reduced expression of IL-17A (Figure S5I).
Finally, ectopic expression of ATF3 rescued IL-17A production
in miR-155-deficient Th17 cells (Figure 5I). In summary, Atf3
has the ability to promote IL-17a expression in Th17 cells.
Jarid2 Is Required for PRC2 Recruitment and
Transcriptional Silencing of Th17-Cell-Associated
Genes
The miR-155-deficient mouse allowed us to assess Th17 cell
development in the context of Jarid2 gain of function. To deter-
mine the direct contribution of Jarid2 during Th17 cell differenti-
ation, we generated Jarid2fl/fl;CD4-cre mice (Figures S6A–S6C).
Mature CD4+ T cells develop in Jarid2fl/fl;CD4-cre mice, and in
contrast to Ezh2-deficient T cells (Su et al., 2005), they do not
display a T cell activation defect (data not shown). We performed
a variant of ChIP-seq that uses lambda 50-30 exonuclease (ChIP-
exo) to reduce background and increase resolution of the assay
(Rhee and Pugh, 2012). In the absence of Jarid2, genomic
recruitment of Suz12 was diminished at theHoxa andHoxd clus-
ters, Il22 and Atf3, for example (Figures S6D–S6G). During
in vitro Th17 cell differentiation, IL-17A, but not IFN-g, expres-
sion was increased in cells from Jarid2fl/fl; CD4-cre mice (Figures872 Immunity 40, 865–879, June 19, 2014 ª2014 Elsevier Inc.6A and 6B). In addition, Il17f, Il22, Il10, Il9, and Atf3 transcripts
were also increased in Jarid2-deficient Th17 cell cultures (Fig-
ures 6C and 6D), whereas no changes were observed in Rorc,
Irf4, and Batf expression (Figures 6C, S6H, and S6I). As confir-
mation, increased amounts of IL-22, IL-10, and IL-9 protein
were detected in the supernatants of Jarid2-deficient Th17 cell
cultures (Figure 6E). Mechanistically, H3K27me3 deposition
was decreased at the Il22, Il10, and Il9 promoters upon Jarid2
ablation (Figure 6F). Moreover, we found augmented amounts
of unspliced message for Il22 and Il9 in Jarid2-deficient Th17
cell cultures, suggesting increased transcription of these cyto-
kine genes (Figure 6G). Thus, lack of Jarid2 results in enhanced
Th17 cytokine gene expression.
Conditional Ablation of Jarid2 Partially Rescues Th17
and Treg Cells in miR-155-Deficient Mice
To determine whether the Th17 and Treg cell phenotypes in
miR-155-deficient mice are caused by increased expression of
Jarid2, we generated double-deficient mice wherein Jarid2 is
conditionally deleted in the T cell lineage of miR-155-deficient
mice. We made mixed BM chimeras of WT (CD45.1+) and dou-
ble-deficient (CD45.2+) cells and infected them with T. gondii
as before to assess IL-17A and IL-22 expression as well as
Treg cell homeostasis. Double-deficient Treg cells were compet-
itive with WT Treg cells whereas miR-155-deficient Treg cells
failed to compete (Figure 7A). In addition, development of
CD4+IL-17A+ T cells was restored in the double-deficient ani-
mals despite IL-22 expression not being rescued (Figure 7B).
Thus, Foxp3+ cells and IL-17A expression in vivo could be
partially restored upon ablation of Jarid2 in miR-155-deficient
T cells (Figures 7C–7E). We recapitulated the rescue of Il17a
and Il17f expression in vitro with double-deficient Th17 cell cul-
tures (Figure 7F). In double-deficient Th17 cell cultures, Atf3
expression was increased compared to WT (Figure S7A).
Furthermore, we found that conditional deletion of one allele
of Jarid2 in miR-155-deficient Th17 cells was sufficient to reduce
Jarid2 protein to near WT levels (Figure 7G) and to rescue IL-17A
expression (Figures 7H and 7I).
Because deletion of Jarid2 in miR-155-deficient CD4+ T cells
did not rescue Il22 expression, we hypothesized that the chro-
matin structure at the Il22 promoter is now in a permissive state
to allow binding of c-MAF, a known repressor. Indeed, in double-
deficient Th17 cell cultures, c-MAF bound to the Il22 promoter
(Figure 7J). Indeed, Suz12 and H3K27me3 enrichment in dou-
ble-deficient Th17 cell cultures were reduced at the Il22 pro-
moter where c-MAF binds (Figures S7B and S7C). Furthermore,
because Il10 expression is regulated by c-MAF (Xu et al., 2009)
and Jarid2-PRC2 (Figure 6C), we checked our c-MAF and
Suz12 ChIP-seq data set and found that c-MAF binding to a pre-
viously reported binding site in the Il10 promoter is restricted
in miR-155-deficient Th17 cells whereas Suz12 occupancy in-
creases (Figure S7D). At this site, c-MAF binding is increased
when bothmiR-155 and Jarid2 are absent (Figure S7E). Globally,
the Jarid2-PRC2 holoenzyme may have the ability to dictate
where transcription factors such as c-MAF can bind chromatin
by affecting the accessibility of different loci to transcription
factors.
In conclusion, we integrated miR-155 and PRC2 with the Th17
cell transcriptional network reported by Ciofani et al. (2012)
Figure 5. Jarid2 Recruits PRC2 to Reprogram the Epigenome of miR-155-Deficient Th17 Cells
(A) Tables summarize Jarid2, Suz12, and H3K27me3 ChIP-seq experiments in Mir155/ and WT Th17 cell cultures. First column is total number of peaks in
Mir155/ and WT identified with SICER 3.1. Second column indicates the number of peaks affected (either increased [[] or decreased [Y]) in Mir155/
compared to WT controls by SICER 3.3.1. Third column indicates the number of RefSeq genes within 10 kb of the peaks in question from SICER 3.3.1.
(B–F) Genome browser screenshots depict Jarid2, Suz12, and H3K27me3 enrichment at theHoxA cluster (B), Tal1 (C), Il10 (D), Il9 (E), andAtf3 (F) loci as a result of
ChIP-seq experiments in Mir155/ (red) and WT (blue) Th17 cells.
(G) Relative expression of Atf3 mRNA by qRT-PCR of Mir155/ and WT Th17 cells. Error bars represent mean ± SEM.
(H) Histogram depicts IL-17A expression from FACS analysis of Th17 cell cultures transduced with ATF3-rv or empty vector (GFP-rv) and gated on transduced
CD4+CD44+GFP+ cells.
(I) Mir155/ Th17 cell cultures transduced with ATF3-rv and gated on transduced (GFP+) or untransduced (GFP) CD4+CD44+ cells.
Statistical significance was determined by Student’s t test (***p < 0.001).
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Figure 6. Absence of Jarid2 in CD4+ T Cells Results in Enhanced Th17 Cell Development
(A and B) FACS analysis of IL-17A and IFN-g expression in CD4+CD44+ cells from Jarid2fl/fl; CD4-cre mice and littermate controls cultured under Th17-cell-
polarizing conditions without IL-1b (A) and the corresponding percentages of CD4+CD44+IL-17A+ T cells (B).
(C) Relative expression of Il17a, Il17f, Atf3, Rorc, Irf4, and Batf mRNA by qRT-PCR from WT and Jarid2-deficient Th17 cell cultures.
(D) Relative expression of Il22, Il9, and Il10 mRNA in Jarid2-deficient and WT Th17 cell cultures was determined by qRT-PCR.
(E) Cytokine concentrations in supernatant of Th17 cell cultures were determined by ELISA.
(F) H3K27me3 at promoters of Il22, Il10, Il9, and Hprt determined by ChIP-qPCR.
(G) qRT-PCR of Il22 intron 4 and Il9 intron 3 of Jarid2-deficient and WT Th17 cell cultures ± reverse transcriptase (RT).
Error bars represent mean ± SEM in (B)–(D), (F), and (G); error bars represent mean ± SD in (E).
Immunity
Epigenetic Reprogramming by Jarid2(Figure S7F). We find that in Th17 cells, the Jarid2-PRC2 com-
plex targets genes that can contribute to IL-17 expression
such as Atf3, cellular plasticity genes such as Tbx21 and Eomes,
and immunoregulatory cytokine genes such as Il22, Il10, and Il9.
In addition to Jarid2, miR-155 appears to repress c-MAF, an
important transcription factor in Th17 cells. We revealed that
Jarid2 restricted c-MAF binding in at least two cases, Il22 and
Il10. Thus, we provide an updated view of the complex regulatory
network in Th17 cells to exemplify how a miRNA might interact
with a chromatin regulator and transcription factors to orches-
trate gene expression programs.874 Immunity 40, 865–879, June 19, 2014 ª2014 Elsevier Inc.DISCUSSION
We highlight a mechanism by which miR-155 regulates the fate
of Th17 and Treg cells. By regulating the expression of Jarid2,
miR-155 can indirectly promote chromatin accessibility and
gene expression. By using ChIP-seq and RNA-seq approaches,
we assessed the genome-wide consequences of Jarid2 upregu-
lation. We observed increased recruitment of PRC2 to genomic
sites accompanied with increased H3K27me3 and silencing of
Il22, Il10, and Il9, cytokines involved in mediating tissue repair
and homeostasis in response to inflammation (Goswami and
Figure 7. Epistasis between Jarid2 and miR-155 in Treg and Th17 Cells
(A andB) FACS analysis ofWT,Mir155/, or double-deficientMir155/; Jarid2fl/fl; CD4-cre (Mir155/; Jarid2/) cells from siLP of infectedmixedBMchimeras
to enumerate CD4+TCRb+CD44+ cells that are IFN-g or Foxp3 positive (A), or IL-17A and/or IL-22 positive (B), 8 days after T. gondii infection.
(C–E) Indicated percentages of CD4+TCRb+CD44+ WT, Mir155/, or Mir155/; Jarid2/ cells from the siLP of infected mixed BM chimeras.
(F) Relative expression of Il17a and Il17f mRNA was determined by qRT-PCR in WT, Mir155/, or Mir155/; Jarid2/ Th17 cell cultures (- exogenous IL-1b).
(G) Immunoblot analysis of Jarid2 and Tubulin protein in WT, Mir155/, and Mir155/; Jarid2+/ Th17 cells.
(H) Histogram depicts intracellular IL-17A expression in WT, Mir155/, and Mir155/; Jarid2+/ Th17 cell cultures (- IL-1b).
(I) The corresponding percentages of CD4+CD44+IL-17A+ T cells.
(J) c-MAF and IgG ChIP-qPCR on the Il22 promoter in WT, Mir155/, and Mir155/; Jarid2/ Th17 cell cultures normalized to input.
Error bars represent mean ± SEM. Statistical significance determined by unpaired Student’s t test (*p < 0.05, **p < 0.01, and ***p < 0.001; ns denotes not
significant).
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Epigenetic Reprogramming by Jarid2Kaplan, 2011; Ouyang et al., 2011; Zenewicz and Flavell,
2011). Although H3K27me3 is often equated with transcriptional
silencing, direct perturbation experiments to address this rela-
tionship are lacking in mammalian systems. Here, we ablated
Jarid2 in CD4+ T cells to prevent recruitment of PRC2, the holo-
enzyme that catalyzes trimethylation of H3K27 at its targets. This
allowed us to identify Jarid2-dependent PRC2 targets genome-
wide and examine the consequences of perturbing this regulato-
ry node on gene expression in Th17 cells. Jarid2-deficient CD4+
T cells undergo enhanced Th17 cell differentiation in part mani-
fested by upregulation of Il17a and Atf3. Reduced or excessive
H3K27me3 catalysis can affect the efficiency of Th17 cell differ-
entiation and Treg cell homeostasis, so miR-155 might have
evolved to modulate PRC2 recruitment by fine-tuning Jarid2
expression.
We found that Il22, Il10, Il9, and Atf3 are among the direct tar-
gets of Jarid2 in Th17 cells, but found additional genes such as
Il17a and Il17f that are affected indirectly. We also observed
increased Jarid2 and PRC2 occupancy in miR-155-deficient
Th17 cell cultures that did not lead to gene expression changes.
Such genes include Tbx21, Eomes, Tal1, and the Hox gene clus-
ters, but because these genes are already silenced in Th17 cells,
increased Jarid2 and PRC2 binding had no additional effect.
Eomes and Tbx21 could mediate T cell fate plasticity, but
because Th17 cells can suppress alternative cell fates via multi-
ple mechanisms (Zhu and Paul, 2010), we did not observe their
derepression in Jarid2-deficient Th17 cell cultures. However,
stimulating Jarid2-deficient Th17 cells with IL-12 or IFN-g or
blocking TGF-b could dramatically change the outcome.
There are several reasons why the consequences of Jarid2
ablation in CD4+ T cells are not more severe. For instance, there
are reports that other DNA-binding factors such as adipocyte
enhancer-binding protein 2 (Kim et al., 2009), metal response
element-binding transcription factor 2 (Li et al., 2011), and addi-
tional sex combs-like homolog 1 (Abdel-Wahab et al., 2012)
can also serve to recruit PRC2 and may act independently or
redundantly with Jarid2. Moreover, there are other mechanisms
responsible for epigenetic marks that need to be considered
such as methylation of H3K9, H4K20, or DNA, which also
mediate transcriptional silencing. Even if the chromatin is poised
for transcription, the factors that are required for transcrip-
tional activation may be absent. For example, we found that
H3K27me3 is reduced at Tbx21 in the absence of Jarid2, but
that without the appropriate signal, its transcriptional enhancer
is not activated (Vahedi et al., 2012). Finally, we looked only for
a relatively local effect (±10 kb), whereas distal regulatory ele-
ments can regulate transcription as far as a megabase away
(Bulger and Groudine, 2011).
Our studies show thatmiR-155 is critical for the in vivo produc-
tion of IL-17A and IL-22, particularly by CD4+ T cells in the gut. In
the absence of miR-155, specification of Th17 cells appears
intact based on RORgt induction, but expression of the signature
cytokine IL-17A is defective. This suggests that miR-155 may
exert its regulatory function more toward the latter phases of dif-
ferentiation as cells are acquiring their effector functions and to a
lesser extent during the initial phases of Th17 cell specification.
Additional evidence supporting this idea comes from our time
course analysis showing that upon in vitro Th17 cell polariza-
tion, miR-155 expression increased over time with the highest876 Immunity 40, 865–879, June 19, 2014 ª2014 Elsevier Inc.expression after 3–4 days. At this stage of Th17 cell differentia-
tion, RORgt expression was already induced by the combined
action of STAT3, BATF, and IRF4 (Ciofani et al., 2012; Yosef
et al., 2013). Like in previous studies, we found that IL-1b en-
hances Th17 cell development in culture (Chung et al., 2009;
Guo et al., 2009; Shaw et al., 2012). IL-1b rescued IL-17 expres-
sion in miR-155-deficient Th17 cell cultures. We believe that IL-1
signaling is promoting IL-17A expression partly through Atf3,
because addition of exogenous IL-1b can upregulate expression
of Atf3 and overexpression of ATF3 in Th17 cells results in
increased IL-17a production. It will be interesting to determine
further the role of Atf3 in Th17 cells.
Here we have expanded the regulatory network that can
modulate cytokine expression in Th17 cells to include post-
transcriptional regulation and histone modification, which may
inspire novel therapeutic avenues. IL-22 plays a dual role in
Th17-cell-mediated inflammation and tissue repair (Dudakov
et al., 2012; Zenewicz and Flavell, 2011; Zheng et al., 2007), so
understanding the mechanisms behind the regulation of Il22
transcription is critical for modulating the immune response dur-
ing an inflammatory disease. For instance, inhibition of miR-155
or promotion of PRC2 activity may be useful for controlling
inflammation. Our work highlights a miR-155-Jarid2 axis that
emanates from the Th17 cell specification program to regulate
cytokine production during the effector phase. Although we
focused on elucidating the Th17 cell network, our in vivo studies
revealed epistasis between miR-155 and Jarid2 in Treg cells.
Thus, it will be interesting to further elucidate the role of Jarid2
in governing Treg cell fate.
Taken together, our study reveals that miR-155 promotes
acquisition of effector functions by regulating a chromatin-modi-
fying complex and thus mediating global changes in gene
expression. A 2-fold change in Jarid2 expression by a miRNA
can reprogram the epigenome of a cell via H3K27 trimethylation.
How miRNAs, transcription factors, and chromatin regulators
cooperate to orchestrate a gene expression program has not
been systematically analyzed. By using Th17 cell differentiation
as a model system, we demonstrate that miR-155 can have pro-
found effects on the chromatin landscape and links posttran-
scriptional, epigenetic, and transcriptional regulation of cellular
differentiation.EXPERIMENTAL PROCEDURES
Mice and Toxoplasma Infection
Mir155-deficient mice (Thai et al., 2007) were backcrossed up to 12 genera-
tions to C57BL/6 mice (Taconic). Atf3-deficient mice on C57BL/6 background
were previously described (Hartman et al., 2004). We obtained a knockout first
conditional allele Jarid2tm1a(KOMP)Wtsi on a C57BL/6 background from the Inter-
national Knockout Mouse Consortium, which we converted into a conditional
allele (Jarid2fl/+) by breeding to Flp transgenic mice (Rodrı´guez et al., 2000).
Then, we bred Jarid2fl/+ mice to CD4-cre transgenic mice (Lee et al., 2001).
For mixed BM reconstitutions, B6.SJL recipient mice (Taconic) were condi-
tionedwith 900 Rads via a Cs137 source prior to injection of threemillion donor
BM cells. Mice were then put on Trimethoprim/Sulfamethoxazole antibiotics
via drinking water for 5 weeks. T. gondii cysts from the Type II avirulent strain
ME-49 were prepared from the brains of infected C57BL/6 mice. For infec-
tions, mice were inoculated by oral gavage with 0.5 ml of PBS for an average
of 50 cysts per animal (Wilson et al., 2010). All mice experiments were done in
compliance with the guidelines of the NIH/NIAID Institutional Animal Care and
Use Committee.
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Epigenetic Reprogramming by Jarid2Cell Isolation and Flow Cytometry
Single-cell suspensions were prepared from spleens and lymph nodes by me-
chanical disruption and filtering through 40 mm cell strainers (BD Biosciences).
Cells were stimulated with 20 ng/ml of phorbol 12-myristate 13-acetate (PMA)
and 1 mg/ml of ionomycin in the presence of BDGolgi Plug containing brefeldin
A for 3–5 hr at 37C. Cells were subsequently stained with fixable viability dye
(eBioscience) and then permeabilized in 500 ml of eBioscience Perm-Fix solu-
tion overnight at 4C. Stained cells were assayed with a BD LSRII flow cytom-
eter or BD LSR Fortessa and results analyzed with FlowJo software. See the
Supplemental Experimental Procedures for additional details and a list of an-
tibodies used.
Retroviral Cloning and Transductions
See the Supplemental Experimental Procedures for details.
RNA Purification and Quantitative PCR
Total RNA extractions were performed with Applied Biosystems mirVana
isolation kit. Applied Biosystems TaqMan Reverse Transcription Reagents
and random hexamers were used to prepare cDNAs. For miRNA quan-
titation, cDNA was prepared with TaqMan microRNA reverse transcrip-
tion kit (Applied Biosystems). Quantitative PCR was performed on a
7900HT Fast Real Time PCR Systems (Applied Biosystems). A list of
primers/probe sets used is included in the Supplemental Experimental
Procedures.
Protein Quantitation
Cell lysates were prepared by lysis in 420 mM NETN buffer containing prote-
ase inhibitor and immunoblotting performed by standard methods. Image J
(http://imagej.nih.gov/ij/) was used to quantify protein expression levels
from digital images of immunoblots and each assay was normalized to
a-Tubulin loading controls. IL-22, IL-9, and IL-10 protein concentrations in
Th17 cell culture supernatants were measured with the corresponding Mouse
ELISA Ready-Set-Go! Kit (eBioscience) according to the manufacturer’s
instructions.
Chromatin Immunoprecipitation
ChIP experimentswere performed as described previously (Wei et al., 2009). In
brief, cells were cross-linked with 2% paraformaldehyde at room temperature
for 15 min and chromatin sheared to 200 base pairs. For ChIP-exo, sheared
chromatin was submitted to Peconic LLC along with antibodies. List of anti-
bodies and validation primers can be found in the Supplemental Experimental
Procedures.
RNA-seq
RNA concentration was determined with the Qubit RNA broad range assay in
the Qubit Fluorometer (Invitrogen) and RNA integrity was determined with
Eukaryote Total RNA Nano Series II ChIP on a 2100 Bioanalyzer (Agilent).
Three independent biological replicates were pooled for RNA-seq. RNA-seq
libraries were prepared from 4 mg of total RNA via the TruSeq RNA sample
prep kit according to manufacturer’s protocol (Illumina). In brief, oligo-dT pu-
rified mRNA was fragmented and subjected to first and second strand cDNA
synthesis. cDNA fragments were blunt-ended, ligated to Illumina adaptors,
and PCR amplified to enrich for the fragments ligated to adaptors. The result-
ing cDNA libraries were verified and quantified on Agilent Bioanalyzer and sin-
gle-end 96 cycle RNA-seq was conducted with the GAIIx Genome Analyzer
(Illumina).
Statistical Significance
GraphPad Prism 5.0 was used for statistical analysis (unpaired, two-tailed,
t test with a confidence interval of 95%). A p value % 0.05 was considered
statistically significant.
ACCESSION NUMBERS
RNA-seq and ChIP-seq data are available in the Gene Expression Omnibus
(GEO) database (http://www.ncbi.nlm.nih.gov/geo) under the accession
numbers GSE37228 and GSE47528.SUPPLEMENTAL INFORMATION
Supplemental Information includes seven figures and Supplemental Experi-
mental Procedures and can be found with this article online at http://dx.doi.
org/10.1016/j.immuni.2014.03.014.
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